Published in J Pharmacol Exp Ther on September 03, 2004
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Advances in male contraception. Endocr Rev (2008) 1.39
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Antiandrogenic properties of parabens and other phenolic containing small molecules in personal care products. Toxicol Appl Pharmacol (2007) 1.13
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology (2005) 0.97
Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res (2006) 0.97
Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv (2005) 0.95
Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology (2008) 0.93
Pharmacologic development of male hormonal contraceptive agents. Clin Pharmacol Ther (2010) 0.84
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis (2014) 0.84
Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol (2015) 0.81
Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev (2017) 0.81
Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study. Drug Metab Dispos (2005) 0.76
Aquaporin-11 control of testicular fertility markers in Syrian hamsters. Mol Cell Endocrinol (2014) 0.76
Synthesis of oxazolidinedione derived bicalutamide analogs. Tetrahedron Lett (2006) 0.75
Cesium fluoride and tetra-n-butylammonium fluoride mediated 1,4-N-->O shift of disubstituted phenyl ring of a bicalutamide derivative. Tetrahedron Lett (2006) 0.75
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol (1994) 1.84
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Enantioselective binding of Casodex to the androgen receptor. Xenobiotica (1996) 1.41
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod (2000) 1.31
Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol (1999) 1.23
Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am (1994) 1.10
Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab (1990) 1.08
Testicular heat exposure enhances the suppression of spermatogenesis by testosterone in rats: the "two-hit" approach to male contraceptive development. Endocrinology (2000) 1.07
Progress towards hormonal male contraception. Trends Pharmacol Sci (2004) 0.94
Endocrine regulation of testicular function in men: implications for contraceptive development. Mol Cell Endocrinol (2001) 0.93
Effect of gonadal steroids on the response to LH-RH in intact and castrated male rats. Endocrinology (1974) 0.87
Effect of sex steroids on pituitary responses to LH-and FSH-releasing hormone in vitro. Endocrinology (1973) 0.85
Effect of testosterone implants on serum gonadotropin concentrations in the male rat. Biol Reprod (1976) 0.84
Biphasic effect of testosterone on spermatogenesis in the rat. Invest Urol (1973) 0.83
The effects of exogenously administered testosterone on spermatogenesis in intact and hypophysectomized rats. Endocrinology (1989) 0.83
ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J Endocrinol (1987) 0.82
Inhibition of luteinizing hormone (LH)-releasing hormone-induced secretion of LH in rat anterior pituitary cell culture by testosterone without conversion to 5 alpha-dihydrotestosterone. Endocrinology (1984) 0.81
Effect of testosterone oenanthate on spermatogenesis and serum testosterone concentrations in adult mice. J Reprod Fertil (1986) 0.80
Inhibition and maintenance of spermatogenesis in rats implanted with polydimethylsiloxane capsules containing various androgens. J Endocrinol (1974) 0.79
Progress towards a male pill. IPPF Med Bull (1997) 0.79
Endogenous antispermatogenic agents: prospects for male contraception. Annu Rev Pharmacol Toxicol (1978) 0.79
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Status of PharmD/PhD programs in colleges of pharmacy: the University of Tennessee dual PharmD/PhD program. Am J Pharm Educ (2006) 2.35
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol (2013) 1.78
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem (2004) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma (2009) 1.58
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett (2004) 1.57
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med (2011) 1.57
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res (2012) 1.49
Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels. Invest Ophthalmol Vis Sci (2012) 1.46
The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology (2007) 1.42
Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgen receptor. J Pharmacol Exp Ther (2003) 1.41
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem (2005) 1.40
Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther (2010) 1.39
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem (2009) 1.27
Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst (2003) 1.25
Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol (2003) 1.25
Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids (2008) 1.24
Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem (2010) 1.21
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res (2010) 1.21
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands. Bioorg Med Chem Lett (2005) 1.19
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. Biochim Biophys Acta (2007) 1.18
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.12
Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules (2002) 1.12
A comprehensive approach to faculty development. Am J Pharm Educ (2006) 1.11
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem (2011) 1.09
Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci (2008) 1.09
Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res (2009) 1.07
Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos (2011) 1.04
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol (2013) 1.03
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res (2013) 1.03
Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res (2012) 1.02
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem (2012) 1.02
Estrogen receptor-{beta}-selective ligands alleviate high-fat diet- and ovariectomy-induced obesity in mice. J Biol Chem (2010) 1.01
Synthesis and photochemical transformation of 3β,21-dihydroxypregna-5,7-dien-20-one to novel secosteroids that show anti-melanoma activity. Steroids (2010) 1.01
MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One (2010) 1.01
Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. Biochem Soc Trans (2012) 1.01
Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. Bioorg Med Chem (2009) 1.01
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res (2003) 1.00
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol (2008) 1.00
Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. J Biol Chem (2004) 0.99
Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorg Med Chem (2011) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell (2013) 0.99
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol (2007) 0.98
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit (2008) 0.98
Structure-activity relationship studies of arylthiazolidine amides as selective cytotoxic agents for melanoma. Anticancer Res (2007) 0.97
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97